Erasca Inc
ERASHealthcare|Biotechnology|USA
$18.53
-0.65 (-3.39%)
Tangible Book
$1.27
About
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Stock Price
+1119.1%(1Y)
Pipeline Summary
10 total trials9
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
Active: 5Recruiting: 2Completed: 2Withdrawn: 1
Active Trials (7)
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
NCT05222802Glioblastoma Multiforme
Phase 1Active
Enrollment: 52 participants
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
NCT06983743Metastatic Solid Tumors
Phase 1Recruiting
Enrollment: 600 participants
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067Advanced or Metastatic NRAS-mutant Melanoma
Phase 3Active
Enrollment: 78 participants
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
NCT07021898Metastatic Solid Tumors
Phase 1Recruiting
Enrollment: 200 participants
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT04670679Advanced or Metastatic Solid Tumors
Phase 1Active
Enrollment: 90 participants
BioScore
3.9/10
Cautious
Ownership
Recent Insider Trades
Garner EbunSELL
2026-04-0180,000 shares @ $16.4
Morris ShannonSELL
2026-03-0420,000 shares @ $15.04
Casdin Alexander W.BUY
2024-05-2180,000 shares @ $2.27
Start Valerie Denise HardingBUY
2023-12-0610,000 shares @ $1.85
Lim Jonathan EBUY
2023-12-061,000,000 shares @ $1.7
Recent News
2026-07-13 09:00:06
2026-07-13 08:00:05
2026-07-13 01:00:02
2026-07-11 03:00:03
2026-07-10 19:00:02
Data last updated: Jul 13, 2026, 12:39 PM